BACKGROUND: We previously developed a reliable and valid method for classifying the intensity of pediatric cancer treatment. The Intensity of Treatment Rating Scale (ITR-2.0) 1 classifies treatments into four operationally defined levels of intensity and is completed by pediatric oncology specialists based on diagnosis, stage, and treatment data from the medical record. Experience with the ITR-2.0 and recent changes in treatment protocols indicated the need for a minor revision and revalidation. METHODS: Five criterion raters reviewed the prior items, independently proposing additions and/or changes in the classification of diseases/treatments. Subsequent to a group discussion of the proposed changes, a revised 43-item ITR was evaluated. Pediatric oncologists (n = 47) completed a two-part online questionnaire. Validity of the classifications was determined by the oncologists classifying each disease/treatment into one of the four levels of intensity. Inter-rater reliability was calculated by having each oncologist classify the treatments of 12 sample patients using the new version which we call the ITR-3. RESULTS: Agreement between median ratings of the 43 items for the pediatric oncologists and the criterion raters was high (r = 0.88). The median of the raters was either identical (81%) with the criterion ratings or discrepant by one level. Inter-rater reliability was very high when using the ITR-3 to classify 12 sample patients, with a median agreement of 0.90 and an intraclass correlation coefficient (r(ICC) = 0.86). CONCLUSIONS: With these minor modifications and updates, the ITR-3 remains a reliable and valid method for classifying pediatric oncology treatment protocols.
BACKGROUND: We previously developed a reliable and valid method for classifying the intensity of pediatric cancer treatment. The Intensity of Treatment Rating Scale (ITR-2.0) 1 classifies treatments into four operationally defined levels of intensity and is completed by pediatric oncology specialists based on diagnosis, stage, and treatment data from the medical record. Experience with the ITR-2.0 and recent changes in treatment protocols indicated the need for a minor revision and revalidation. METHODS: Five criterion raters reviewed the prior items, independently proposing additions and/or changes in the classification of diseases/treatments. Subsequent to a group discussion of the proposed changes, a revised 43-item ITR was evaluated. Pediatric oncologists (n = 47) completed a two-part online questionnaire. Validity of the classifications was determined by the oncologists classifying each disease/treatment into one of the four levels of intensity. Inter-rater reliability was calculated by having each oncologist classify the treatments of 12 sample patients using the new version which we call the ITR-3. RESULTS: Agreement between median ratings of the 43 items for the pediatric oncologists and the criterion raters was high (r = 0.88). The median of the raters was either identical (81%) with the criterion ratings or discrepant by one level. Inter-rater reliability was very high when using the ITR-3 to classify 12 sample patients, with a median agreement of 0.90 and an intraclass correlation coefficient (r(ICC) = 0.86). CONCLUSIONS: With these minor modifications and updates, the ITR-3 remains a reliable and valid method for classifying pediatric oncology treatment protocols.
Authors: Kimberly Whelan; Kayla Stratton; Toana Kawashima; Wendy Leisenring; Susan Hayashi; John Waterbor; Julie Blatt; Charles A Sklar; Roger Packer; Pauline Mitby; Leslie L Robison; Ann C Mertens Journal: Pediatr Blood Cancer Date: 2011-02-15 Impact factor: 3.167
Authors: Meredith J Lutz Stehl; Anne E Kazak; Wei-Ting Hwang; Ahna L H Pai; Anne F Reilly; Steven D Douglas Journal: Neuroimmunomodulation Date: 2008-08-05 Impact factor: 2.492
Authors: Meredith Lutz Stehl; Anne E Kazak; Melissa A Alderfer; Alyssa Rodriguez; Wei-Ting Hwang; Ahna L H Pai; Alexandra Boeving; Anne Reilly Journal: J Pediatr Psychol Date: 2008-12-17
Authors: Maria C McCarthy; Naomi E Clarke; Alasdair Vance; David M Ashley; John A Heath; Vicki A Anderson Journal: Pediatr Blood Cancer Date: 2009-07 Impact factor: 3.167
Authors: Melissa A Alderfer; Ifigenia Mougianis; Lamia P Barakat; David Beele; Susan DiTaranto; Wei-Ting Hwang; Anne T Reilly; Anne E Kazak Journal: Cancer Date: 2009-09-15 Impact factor: 6.860
Authors: Branlyn E Werba; Wendy Hobbie; Anne E Kazak; Richard F Ittenbach; Anne F Reilly; Anna T Meadows Journal: Pediatr Blood Cancer Date: 2007-06-15 Impact factor: 3.167
Authors: Ahna L H Pai; Anna Maria Patiño-Fernández; Mary McSherry; David Beele; Melissa A Alderfer; Anne T Reilly; Wei-Ting Hwang; Anne E Kazak Journal: J Pediatr Psychol Date: 2007-07-03
Authors: Jocelyn M York; James L Klosky; Yanjun Chen; James A Connelly; Karen Wasilewski-Masker; Anna R Giuliano; Leslie L Robison; F Lennie Wong; Melissa M Hudson; Smita Bhatia; Wendy Landier Journal: J Clin Oncol Date: 2020-06-18 Impact factor: 44.544
Authors: Matthew C Hocking; Wendy L Hobbie; Janet A Deatrick; Thomas L Hardie; Lamia P Barakat Journal: J Adolesc Young Adult Oncol Date: 2015-03 Impact factor: 2.223
Authors: Bethany D Nugent; Catherine M Bender; Susan M Sereika; Jean M Tersak; Margaret Rosenzweig Journal: J Adolesc Young Adult Oncol Date: 2017-08-07 Impact factor: 2.223
Authors: Kristin C Marr; Mohammad Agha; Rinku Sutradhar; Jason D Pole; David Hodgson; Astrid Guttmann; Mark Greenberg; Paul C Nathan Journal: J Cancer Surviv Date: 2017-08-07 Impact factor: 4.442